business / news / / MarketScreener
Wegovy HD is a once-weekly injection that contains 7.2 milligrams of active ingredient semaglutide.
Novo Nordisk launched Wegovy HD, a 7.2 mg semaglutide injection, in the U.S.
KEY POINTS
- Wegovy HD enables average weight loss of 21% over 18 months in non-diabetic obese adults.
- Previously, the highest Wegovy dose was 2.4 mg, yielding about 18% average weight loss.
- Novo Nordisk seeks EU and U.K. approval for a 7.2 mg single-dose pen, decision expected later this year.
COMPANIES
Summarized by Newsio from MarketScreener. How we summarize →